MedDataX Logo

The Survey About Resting Metabolic Rate and Its Related Factors in Terminal Patients

NCT ID: NCT00208013

Last Updated: 2010-11-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cachectic patients often lose their appetite, lose weight, and are prone to weakness and even death in advanced illness. Nutrition therapy is important and of concern to the investigators in cancer patients. More than 80% of terminal cancer or advanced illness patients get cachexia. Cachexia is a complex, multifactorial syndrome that results from a reduction in food intake, a variety of metabolic abnormalities (including hypermetabolism) or more often a combination of the two. Cachexia will progress with disease progression. Cachexia or weight loss is often the major cause of death or poor quality of life.

The change of resting energy expenditure (REE) is different in various tumor types. Most experts agree that the REE will increase in cancer cachexia syndrome. The more weight loss, the more cachexia will occur.

Overnutrition is not beneficial in terminal patients according to the Chiu and Easson studies. As the investigators know, few studies focus on REE in terminal patients. In this study, samples are from a hospice palliative ward or from hospice home care patients in a medical center in mid-Taiwan. About 100 patients will be recruited. The investigators will analyze the relationship between REE and its related factors. After finishing the study, they will provide more evidence for treating cachexia in terminal patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

According to data from the Taiwanese government, cancer mortality has been the leading cause of death in Taiwan since 1982. The trend is increasing day by day. As the people are aging in Taiwan, the incidence of cancer will increase and it will be more important than before.

Cachectic patients often lose their appetite, lose weight, and are prone to weakness and even death in advanced illness. Nutrition therapy is important and of concern to the investigators in cancer patients. More than 80% of terminal cancer or advanced illness patients get cachexia. Cachexia is a complex, multifactorial syndrome that results from a reduction in food intake, a variety of metabolic abnormalities (including hypermetabolism) or more often a combination of the two. Cachexia will progress with disease progression. Cachexia or weight loss is often the major cause of death or poor quality of life.

The change of resting energy expenditure (REE) is different in various tumor types. Most experts agree that the REE will increase in cancer cachexia syndrome. The more weight loss, the more cachexia will occur.

Overnutrition is not beneficial in terminal patients according to the Chiu and Easson studies. As the investigators know, few studies focus on REE in terminal patients. In this study, samples are from a hospice palliative ward or from hospice home care patients in a medical center in mid-Taiwan. About 100 patients will be recruited. The investigators will analyze the relationship between REE and its related factors. After finishing the study, they will provide more evidence for treating cachexia in terminal patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Cancers

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

resting energy expenditure cachexia advanced cancer advanced cancer patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Terminal cancer patients who were admitted to a hospice palliative ward in one medical center located in mid-Taiwan

Exclusion Criteria

* Patient could not complete the examination of resting metabolic rate using MedGerm
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

China Medical University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

China Medical University Hospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wen-Yuan Lin, M.D.

Role: PRINCIPAL_INVESTIGATOR

China Medical University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CMUH

Taichung, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

94-2314-B-039-025

Identifier Type: -

Identifier Source: org_study_id